(Total Views: 518)
Posted On: 11/07/2023 1:15:34 PM
Post# of 156820
Re: generactor #138833
That’s a poor excuse being blind to something well millions of people were dying.
Unless remdesivir was some miracle drug, which we know it wasn’t, why would he completely dismiss a potential better drug to treat covid.
I think he has to explain himself or anyone else that was involved with Leronlimab. People died, mistakes were made. As long as you acted in good faith, fine things happen, the system isn’t perfect.
However, anyone that worked for the FDA owes the public a response. I’m a public employee and I never have an issue being investigated because I do what’s right, if anything I enjoy transparency. Same goes for these employees they should embrace it. Could you imagine if these people had to wear body cameras. I bet you some of them are deleting emails as we speak! Ok maybe not. You get my point.
However, the fact some of them lurked on here and still didn’t understand how Leronlimab worked is disturbing. At the very least Leronlimab deserves a fair shake.
Once again you stop giving a drug after two weeks. That is absolutely the dumbest thing anyone could ever do during a trial especially when the CMO, at the time, highly recommended 4 weeks of treatment along with other individuals. You can’t make an argument against that? Can someone explain why this would make sense?
Maybe the FDA can explain this. Regardless we deserve answers, hopefully we get them. If not we should demand them at some point, but it looks like there is questions being asked at the highest levels. It’s a start.
Sorry just frustrated after reading Dr Jays email. Maybe a little more context will help me see things differently.
Unless remdesivir was some miracle drug, which we know it wasn’t, why would he completely dismiss a potential better drug to treat covid.
I think he has to explain himself or anyone else that was involved with Leronlimab. People died, mistakes were made. As long as you acted in good faith, fine things happen, the system isn’t perfect.
However, anyone that worked for the FDA owes the public a response. I’m a public employee and I never have an issue being investigated because I do what’s right, if anything I enjoy transparency. Same goes for these employees they should embrace it. Could you imagine if these people had to wear body cameras. I bet you some of them are deleting emails as we speak! Ok maybe not. You get my point.
However, the fact some of them lurked on here and still didn’t understand how Leronlimab worked is disturbing. At the very least Leronlimab deserves a fair shake.
Once again you stop giving a drug after two weeks. That is absolutely the dumbest thing anyone could ever do during a trial especially when the CMO, at the time, highly recommended 4 weeks of treatment along with other individuals. You can’t make an argument against that? Can someone explain why this would make sense?
Maybe the FDA can explain this. Regardless we deserve answers, hopefully we get them. If not we should demand them at some point, but it looks like there is questions being asked at the highest levels. It’s a start.
Sorry just frustrated after reading Dr Jays email. Maybe a little more context will help me see things differently.
(4)
(0)
Daniel Rizzo
Federal Whistleblower
Case Numbers:
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
DOD Case #16282
IC IG / 50 U.S.C. §3033
ARPA-H (Advanced Research Projects Agency for Health)
Founder & CEO of FireGate Bioscience
USPTO: Inventor of the HIV Cure Protocol
https://investorshangout.com/images/MYImages/...G_2859.png
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com
The underlying data is protected under federal law specifically 42 U.S.C. § 289b and its implementing regulation, 42 C.F.R. Part 93 through the Office of Research Integrity (askORI) within HHS, and coordinated with the Office of the Secretary / Office of Public Health and Science (OS/OPHS).
- Waiting…
whistleblower_complaints@wyden.senate.gov belongs to Senator Ron Wyden, a senior Democratic U.S. Senator from Oregon.
We are watching YOU……
“This isn’t conspiracy, this is criminal suppression.” - Ohm
https://www.justice.gov/usao-sdny/pr/us-attor...r-programs
https://investorshangout.com/images/MYImages/..._3015.jpeg
???? What Leronlimab Does
• Target: CCR5 receptor (the same receptor people with the CCR5Δ32 mutation lack — like the “Berlin” and “London” patients who were cured after stem cell transplants).
• Effect: By binding CCR5, leronlimab blocks HIV entry into CD4 cells.
• Trial Data:
• In combination therapy trials, ~81% of patients achieved viral loads <50 copies/mL (suppression, not cure).
• As monotherapy, some patients maintained suppression for long stretches (months), but not universally.
⸻
???? Why It Might Be Seen as a “Cure”
• In theory, if you completely block CCR5 on all relevant cells, HIV can’t infect new cells.
• If existing infected reservoirs naturally decay without replenishment, the virus could eventually vanish.
• That’s exactly what happened in the Berlin/London patients — except through stem cell transplants with CCR5Δ32 donors, not a drug.
⸻
???? Why It Hasn’t Been Called a Cure (Yet)
1. HIV Reservoirs Persist
Leronlimab blocks new infection, but it doesn’t flush latent virus from cells. Once treatment stops, those reservoirs can reignite infection.
2. CCR5-Independent Pathways
Some HIV strains use CXCR4 or dual-tropism (CCR5 + CXCR4). Leronlimab won’t stop those.
3. Clinical Conservatism
Researchers avoid using the word “cure” unless patients remain off all therapy with no viral rebound for years. Leronlimab hasn’t shown that in trials.
⸻
???? So Could It Alone Cure HIV?
• In select cases (if someone’s virus is purely CCR5-tropic and their reservoirs naturally decay): maybe.
• But in the general population, it’s unlikely as a monotherapy cure. More realistic is using it as part of a cure combo approach…
Federal Whistleblower
Case Numbers:
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
DOD Case #16282
IC IG / 50 U.S.C. §3033
ARPA-H (Advanced Research Projects Agency for Health)
Founder & CEO of FireGate Bioscience
USPTO: Inventor of the HIV Cure Protocol
https://investorshangout.com/images/MYImages/...G_2859.png
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com
The underlying data is protected under federal law specifically 42 U.S.C. § 289b and its implementing regulation, 42 C.F.R. Part 93 through the Office of Research Integrity (askORI) within HHS, and coordinated with the Office of the Secretary / Office of Public Health and Science (OS/OPHS).
- Waiting… whistleblower_complaints@wyden.senate.gov belongs to Senator Ron Wyden, a senior Democratic U.S. Senator from Oregon.
We are watching YOU……
“This isn’t conspiracy, this is criminal suppression.” - Ohm
https://www.justice.gov/usao-sdny/pr/us-attor...r-programs
https://investorshangout.com/images/MYImages/..._3015.jpeg
???? What Leronlimab Does
• Target: CCR5 receptor (the same receptor people with the CCR5Δ32 mutation lack — like the “Berlin” and “London” patients who were cured after stem cell transplants).
• Effect: By binding CCR5, leronlimab blocks HIV entry into CD4 cells.
• Trial Data:
• In combination therapy trials, ~81% of patients achieved viral loads <50 copies/mL (suppression, not cure).
• As monotherapy, some patients maintained suppression for long stretches (months), but not universally.
⸻
???? Why It Might Be Seen as a “Cure”
• In theory, if you completely block CCR5 on all relevant cells, HIV can’t infect new cells.
• If existing infected reservoirs naturally decay without replenishment, the virus could eventually vanish.
• That’s exactly what happened in the Berlin/London patients — except through stem cell transplants with CCR5Δ32 donors, not a drug.
⸻
???? Why It Hasn’t Been Called a Cure (Yet)
1. HIV Reservoirs Persist
Leronlimab blocks new infection, but it doesn’t flush latent virus from cells. Once treatment stops, those reservoirs can reignite infection.
2. CCR5-Independent Pathways
Some HIV strains use CXCR4 or dual-tropism (CCR5 + CXCR4). Leronlimab won’t stop those.
3. Clinical Conservatism
Researchers avoid using the word “cure” unless patients remain off all therapy with no viral rebound for years. Leronlimab hasn’t shown that in trials.
⸻
???? So Could It Alone Cure HIV?
• In select cases (if someone’s virus is purely CCR5-tropic and their reservoirs naturally decay): maybe.
• But in the general population, it’s unlikely as a monotherapy cure. More realistic is using it as part of a cure combo approach…
